HuGE Literature Finder
Records 1-9
|
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Cancer medicine 2018 May . Werner Theresa L, Sachdev Jasgit, Swisher Elizabeth M, Gutierrez Martin, Kittaneh Muaiad, Stein Mark N, Xiong Hao, Dunbar Martin, Sullivan Danielle, Komarnitsky Philip, McKee Mark, Tan Antoinette |
|
Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
The journal of prevention of Alzheimer's disease 2017 4 (3): 149-156. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey J A, Power A, Wang P, Shen L, Tolar |
|
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
European journal of cancer (Oxford, England : 1990) 2015 Dec 54 11-17. Flinn Ian W, Bartlett Nancy L, Blum Kristie A, Ardeshna Kirit M, LaCasce Ann S, Flowers Christopher R, Shustov Andrei R, Thress Kenneth S, Mitchell Patrick, Zheng Fred, Skolnik Jeffrey M, Friedberg Jonathan |
|
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
|
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
American journal of hematology 2015 Apr 90 (4): 276-81. Strati Paolo, Kantarjian Hagop, Ravandi Farhad, Nazha Aziz, Borthakur Gautam, Daver Naval, Kadia Tapan, Estrov Zeev, Garcia-Manero Guillermo, Konopleva Marina, Rajkhowa Trivikram, Durand Menda, Andreeff Michael, Levis Mark, Cortes Jor |
|
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
British journal of cancer 2013 Nov 109 (11): 2803-9. Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa |
|
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Cancer chemotherapy and pharmacology 2013 Nov 72 (5): 953-64. Park Sook Ryun, Hong Yong Sang, Lim Hyeong-Seok, Seong Moon-Woo, Kong Sun-Young, Kim Sun Young, Park Young-Iee, Jung Kyung H |
|
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Clinical therapeutics 2010 Nov 32 (12): 2003-11. Pan Xiaolin, Li Yuqing, Qiu Yuping, Tang Qiyun, Qian Bingbing, Yao Linhua, Shi Ruihua, Zhang Guox |
|
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
Cancer chemotherapy and pharmacology 2009 Feb 63 (3): 477-89. O'Bryant C L, Lieu C H, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz M K, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt S |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 27, 2021
- Content source: